Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

CONCLUSION: Brentuximab vedotin had a positive benefit-risk profile for Chinese patients with R/R cHL or sALCL confirming it as a potential treatment option.CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT02939014.PMID:34275403 | DOI:10.1080/17474086.2021.1942831

Source: Expert Review of Hematology - July 19, 2021 Category: Hematology Authors: Yuqin Song Ye Guo Huiqiang Huang Wei Li Xiaoyan Ke Jifeng Feng Wei Xu Harry Miao Judith Kinley Gregory Song Yi Dai Hui Wang Jun Zhu Source Type: research